S&P 500   4,313.13 (+0.45%)
DOW   33,925.43 (+0.27%)
QQQ   357.16 (+1.14%)
AAPL   181.84 (+0.70%)
MSFT   328.57 (+1.02%)
META   267.37 (+1.05%)
GOOGL   123.52 (+1.13%)
AMZN   125.40 (+0.93%)
TSLA   250.41 (+6.62%)
NVDA   395.00 (+2.57%)
NIO   8.33 (+6.93%)
BABA   86.23 (+0.10%)
AMD   126.47 (+4.48%)
T   16.08 (+0.06%)
F   13.99 (+3.02%)
MU   65.92 (+0.92%)
CGC   0.68 (-1.35%)
GE   105.78 (-0.27%)
DIS   92.32 (-0.23%)
AMC   4.72 (+0.85%)
PFE   39.47 (+0.97%)
PYPL   63.19 (-1.63%)
NFLX   419.65 (+2.51%)
S&P 500   4,313.13 (+0.45%)
DOW   33,925.43 (+0.27%)
QQQ   357.16 (+1.14%)
AAPL   181.84 (+0.70%)
MSFT   328.57 (+1.02%)
META   267.37 (+1.05%)
GOOGL   123.52 (+1.13%)
AMZN   125.40 (+0.93%)
TSLA   250.41 (+6.62%)
NVDA   395.00 (+2.57%)
NIO   8.33 (+6.93%)
BABA   86.23 (+0.10%)
AMD   126.47 (+4.48%)
T   16.08 (+0.06%)
F   13.99 (+3.02%)
MU   65.92 (+0.92%)
CGC   0.68 (-1.35%)
GE   105.78 (-0.27%)
DIS   92.32 (-0.23%)
AMC   4.72 (+0.85%)
PFE   39.47 (+0.97%)
PYPL   63.19 (-1.63%)
NFLX   419.65 (+2.51%)
S&P 500   4,313.13 (+0.45%)
DOW   33,925.43 (+0.27%)
QQQ   357.16 (+1.14%)
AAPL   181.84 (+0.70%)
MSFT   328.57 (+1.02%)
META   267.37 (+1.05%)
GOOGL   123.52 (+1.13%)
AMZN   125.40 (+0.93%)
TSLA   250.41 (+6.62%)
NVDA   395.00 (+2.57%)
NIO   8.33 (+6.93%)
BABA   86.23 (+0.10%)
AMD   126.47 (+4.48%)
T   16.08 (+0.06%)
F   13.99 (+3.02%)
MU   65.92 (+0.92%)
CGC   0.68 (-1.35%)
GE   105.78 (-0.27%)
DIS   92.32 (-0.23%)
AMC   4.72 (+0.85%)
PFE   39.47 (+0.97%)
PYPL   63.19 (-1.63%)
NFLX   419.65 (+2.51%)
S&P 500   4,313.13 (+0.45%)
DOW   33,925.43 (+0.27%)
QQQ   357.16 (+1.14%)
AAPL   181.84 (+0.70%)
MSFT   328.57 (+1.02%)
META   267.37 (+1.05%)
GOOGL   123.52 (+1.13%)
AMZN   125.40 (+0.93%)
TSLA   250.41 (+6.62%)
NVDA   395.00 (+2.57%)
NIO   8.33 (+6.93%)
BABA   86.23 (+0.10%)
AMD   126.47 (+4.48%)
T   16.08 (+0.06%)
F   13.99 (+3.02%)
MU   65.92 (+0.92%)
CGC   0.68 (-1.35%)
GE   105.78 (-0.27%)
DIS   92.32 (-0.23%)
AMC   4.72 (+0.85%)
PFE   39.47 (+0.97%)
PYPL   63.19 (-1.63%)
NFLX   419.65 (+2.51%)
NYSE:ZTS

Zoetis (ZTS) Competitors

$163.76
-0.54 (-0.33%)
(As of 10:33 AM ET)
Compare
Today's Range
$162.95
$164.20
50-Day Range
$161.00
$186.23
52-Week Range
$124.15
$187.82
Volume
242,181 shs
Average Volume
2.05 million shs
Market Capitalization
$75.68 billion
P/E Ratio
36.97
Dividend Yield
0.92%
Price Target
$221.14

ZTS vs. HZNP, BMY, PFE, MRK, REGN, VRTX, GSK, TAK, SNY, and GMAB

Should you be buying Zoetis stock or one of its competitors? The main competitors of Zoetis include Horizon Therapeutics Public (HZNP), Bristol-Myers Squibb (BMY), Pfizer (PFE), Merck & Co., Inc. (MRK), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), GSK (GSK), Takeda Pharmaceutical (TAK), Sanofi (SNY), and Genmab A/S (GMAB). These companies are all part of the "pharmaceutical preparations" industry.

Zoetis vs.

Horizon Therapeutics Public (NASDAQ:HZNP) and Zoetis (NYSE:ZTS) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership, community ranking and media sentiment.

In the previous week, Horizon Therapeutics Public had 8 more articles in the media than Zoetis. MarketBeat recorded 10 mentions for Horizon Therapeutics Public and 2 mentions for Zoetis. Zoetis' average media sentiment score of 0.81 beat Horizon Therapeutics Public's score of 0.47 indicating that Zoetis is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Horizon Therapeutics Public
3 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Zoetis
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Zoetis has higher revenue and earnings than Horizon Therapeutics Public. Zoetis is trading at a lower price-to-earnings ratio than Horizon Therapeutics Public, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Horizon Therapeutics Public$3.58 billion6.36$521.48 million$1.5962.53
Zoetis$8.08 billion9.40$2.11 billion$4.4337.09

Horizon Therapeutics Public currently has a consensus price target of $111.42, indicating a potential upside of 12.07%. Zoetis has a consensus price target of $221.14, indicating a potential upside of 34.61%. Given Zoetis' stronger consensus rating and higher possible upside, analysts clearly believe Zoetis is more favorable than Horizon Therapeutics Public.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Horizon Therapeutics Public
0 Sell rating(s)
8 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.27
Zoetis
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
3.00

Zoetis has a net margin of 25.59% compared to Horizon Therapeutics Public's net margin of 10.40%. Zoetis' return on equity of 50.26% beat Horizon Therapeutics Public's return on equity.

Company Net Margins Return on Equity Return on Assets
Horizon Therapeutics Public 10.40% 20.31% 11.37%
Zoetis 25.59% 50.26% 16.24%

91.0% of Horizon Therapeutics Public shares are owned by institutional investors. Comparatively, 90.2% of Zoetis shares are owned by institutional investors. 2.5% of Horizon Therapeutics Public shares are owned by company insiders. Comparatively, 0.1% of Zoetis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Horizon Therapeutics Public has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Comparatively, Zoetis has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500.

Horizon Therapeutics Public received 26 more outperform votes than Zoetis when rated by MarketBeat users. Likewise, 78.15% of users gave Horizon Therapeutics Public an outperform vote while only 77.57% of users gave Zoetis an outperform vote.

CompanyUnderperformOutperform
Horizon Therapeutics PublicOutperform Votes
894
78.15%
Underperform Votes
250
21.85%
ZoetisOutperform Votes
868
77.57%
Underperform Votes
251
22.43%

Summary

Zoetis beats Horizon Therapeutics Public on 11 of the 18 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ZTS vs. The Competition

MetricZoetisPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$75.92B$6.17B$4.63B$14.98B
Dividend Yield0.88%2.60%2.44%3.95%
P/E Ratio37.0910.13145.9521.71
Price / Sales9.40166.083,421.6413.05
Price / Cash28.7120.6191.3223.82
Price / Book17.394.854.727.36
Net Income$2.11B$197.45M$118.16M$902.88M
7 Day Performance-4.43%0.95%1.38%2.59%
1 Month Performance-10.89%1.48%1.96%4.86%
1 Year Performance-1.32%16.90%8.87%-4.33%

Zoetis Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HZNP
Horizon Therapeutics Public
2.3057 of 5 stars
$99.80
+0.1%
$111.42
+11.6%
+9.7%$22.82B$3.63B62.772,115Analyst Report
Options Volume
BMY
Bristol-Myers Squibb
2.3896 of 5 stars
$65.48
-0.8%
$78.62
+20.1%
-14.3%$137.56B$45.85B19.0934,300
PFE
Pfizer
3.0474 of 5 stars
$38.37
-0.7%
$47.33
+23.4%
-26.9%$216.58B$92.95B7.5583,000
MRK
Merck & Co., Inc.
2.867 of 5 stars
$110.00
-2.7%
$120.75
+9.8%
+23.3%$279.12B$59.28B21.4869,000
REGN
Regeneron Pharmaceuticals
2.5432 of 5 stars
$748.14
-0.3%
$854.13
+14.2%
+23.4%$81.79B$12.37B20.3311,851Analyst Report
VRTX
Vertex Pharmaceuticals
2.4286 of 5 stars
$330.41
-1.2%
$353.87
+7.1%
+21.1%$85.10B$8.93B26.314,800Analyst Report
GSK
GSK
2.3471 of 5 stars
$34.62
+1.0%
N/A-21.4%$70.88B$36.28B4.1869,400Analyst Revision
TAK
Takeda Pharmaceutical
2.1774 of 5 stars
$16.36
+2.0%
$24.67
+50.8%
+18.9%$51.76B$29.81B21.2447,347
SNY
Sanofi
2.483 of 5 stars
$51.49
+1.3%
$94.50
+83.5%
-2.5%$129.85B$45.31B18.4691,573
GMAB
Genmab A/S
2.354 of 5 stars
$39.15
0.0%
$39.15
0.0%
+25.1%$25.83B$2.07B35.271,660

Related Companies and Tools

This page (NYSE:ZTS) was last updated on 6/9/2023 by MarketBeat.com Staff

My Account -